BeiGene Medical Europe
 Sign in
 
  • Virtual Congress
  • BeiGeneius Webinars
  • BeiGeneius Resources
  • About us
  • beigenemedical.info

Tislelizumab monotherapy in HCC: Health-Related QoL

 Back  View
Tislelizumab monotherapy in HCC:  Health-Related QoL
 POSTER   09/2021
 View

Rating

Rate this resource

Related resources

Memo inOncology - ESMO 2021 Congress Report
Memo inOncology - ESMO 2021 Congress Report
Tislelizumab - Mode of Action
Tislelizumab - Mode of Action
Investigation of PD‑L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with ventana PD-L1 (SP263) assay and combined positive score (CPS)
Investigation of PD‑L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with ventana PD-L1 (SP263) assay and combined positive score (CPS)
 Back

This function is only available for registered users.

BeiGene Medical EU
Welcome to the BeiGene EU Medical Information Website
EuropeWorldItalySpain
I am not a healthcare professional
You are now leaving the website of BeiGene Europe (beigenemedical.info)
You are now leaving the italian website of BeiGene EU.
BeiGene Medical EU
Please check your webbrowser
BeiGene Medical Europe
beigenemedical.eu
  • Virtual Congress
  • About us
This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.

As part of scientific exchange, BeiGene is providing the most recent abstract(s) accepted by the referenced scientific congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of BeiGene products.
© 2022 BeiGene. All Rights Reserved.
Privacy Policy | Terms of use | Imprint |